PrEP for HIV prevention in high-risk adults in Thailand
Part of Infections clinical trials.
This trial checks how well PrEP pills (TDF/FTC) prevent HIV in people who are at high risk and are HIV-negative. It may help you understand whether PrEP is a good prevention option for your situation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be older than 18 years
- You must test negative for HIV during screening
- Your kidney function must be good (creatinine clearance over 60 mL/min)
- You must not have an allergy or other problem taking PrEP pills (TDF/FTC)
- In the last 6 months, you must have at least one HIV risk factor, such as unprotected sex with a high-risk partner, many partners, an STI, or using prevention/PEP before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people who got exposed to HIV despite taking the long-acting PrEP shot (cabotegravir). It tests different pill-based HIV treatment plans to find the best option for them.
This study tests how taking two tablets of a PrEP medication (F/TAF) at once affects healthy volunteers. It helps us understand the safety and how the body processes the drug.
This study tests a program to help adolescent girls and young women at high risk of HIV take PrEP consistently. It aims to improve access and adherence to PrEP, a daily pill that prevents HIV.
This study aims to reduce HIV stigma and improve PrEP use among young transgender women in Thailand. It is testing a new program to help those who are not already taking PrEP consistently.
This study looks at how taking PrEP (medicine to prevent HIV) affects HIV prevention and how much it costs in real life. You may be able to join if you are HIV-negative and are interested in starting, currently using, or have used PrEP before.
This study tests an all-in-one HIV prevention package for young men at higher risk of HIV. It combines a new long-acting PrEP (injectable HIV prevention) with mobile health support and sexually transmitted infection prevention. The goal is to see if this comprehensive approach works better than standard care.
Hear when a new HIV Prevention trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.